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Abstract
Background: PUMA is a pro-apoptotic Bcl-2 family member that has been shown to be involved
in apoptosis in many cell types. We sought to ascertain whether induction of PUMA plays a crucial
role in E2F-1-induced apoptosis in melanoma cells.
Methods:  PUMA gene and protein expression levels were detected by real-time PCR and
Western blot in SK-MEL-2 and HCT116 cell lines after Ad-E2F-1 infection. Activation of the PUMA
promoter by E2F-1 overexpression was detected by dual luciferase reporter assay. E2F-1-induced
Bax translocation was shown by immunocytochemistry. The induction of caspase-9 activity was
measured by caspase-9 colorimetric assay kit.
Results: Up-regulation of the PUMA gene and protein by E2F-1 overexpression was detected by
real-time PCR and Western blot analysis in the SK-MEL-2 melanoma cell line. In support of this
finding, we found six putative E2F-1 binding sites within the PUMA promoter. Subsequent dual
luciferase reporter assay showed that E2F-1 expression could increase the PUMA gene promoter
activity 9.3 fold in SK-MEL-2 cells. The role of PUMA in E2F-1-induced apoptosis was further
investigated in a PUMA knockout cell line. Cell viability assay showed that the HCT116 PUMA-/-
cell line was more resistant to Ad-E2F-1-mediated cell death than the HCT116 PUMA+/+ cell line.
Moreover, a 2.2-fold induction of the PUMA promoter was also noted in the HCT116 PUMA+/+
colon cancer cell line after Ad-E2F-1 infection. Overexpression of a truncated E2F-1 protein that
lacks the transactivation domain failed to up-regulate PUMA promoter, suggesting that PUMA may
be a transcriptional target of E2F-1. E2F-1-induced cancer cell apoptosis was accompanied by Bax
translocation from the cytosol to mitochondria and the induction of caspase-9 activity, suggesting
that E2F-1-induced apoptosis is mediated by PUMA through the cytochrome C/Apaf-1-dependent
pathway.
Conclusion: Our studies strongly demonstrated that E2F-1 induces melanoma cell apoptosis via
PUMA up-regulation and Bax translocation. The signaling pathways provided here will further
enhance insights on the mechanisms of E2F-1-induced cancer cell apoptosis as a strategy for cancer
therapy.
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Background
E2F-1 is the best characterized member of the E2F family
of transcription factors, which is comprised of six mem-
bers that have the ability to regulate the cell cycle. The E2F
family regulates overlapping sets of target genes, and all
contain related DNA binding and dimerization domains.
All members of the family except E2F-6 also contain a
transactivation domain [1]. Overexpression of E2F-1 has
demonstrated induction of S-phase entry as well as apop-
tosis [2]. Our previous studies have shown that infection
of Ad-E2F-1, an adenovirus vector that expresses the full-
length E2F-1 gene, can efficiently induce apoptosis in a
wide spectrum of cancer cells in vitro as well as in vivo [3-
5]. So far, E2F-1 has been implicated in the induction of
apoptosis through p53-dependent and p53-independent
pathways [6,7]. Several genes involved in the activation or
execution of apoptosis recently have been identified as
E2F-1 target genes, such as p14/p19ARF and p73 [6-10].
However, the molecular mechanisms underlying E2F-1-
induced apoptosis are far from being fully understood.
Bcl-2 family members, which consist of both anti- and
pro-apoptotic molecules, are major regulators of apopto-
sis [11]. PUMA (p53 up-regulated modulator of apopto-
sis) belongs to a subset of the Bcl-2 family – the pro-
apoptotic BH3-only family. It shares only the amphip-
athic α-helical BH3 region with the rest of the Bcl-2 family
members [12,13]. BH3-only members, including PUMA,
Bid, Bad, Bim, and Noxa, serve to integrate diverse apop-
totic stimuli into a common cell death pathway governed
by other multi-domain Bcl-2 family members, such as Bax
and Bak [14]. In healthy cells, Bax exists mainly in the
cytosol in an inactive form. In response to apoptotic sig-
nals, Bax can be induced to undergo a conformational
change and migrate from the cytosol to the mitochondria
[15,16]. The conformationally altered Bax protein oli-
gomerizes on the mitochondrial outer membrane,
induces cytochrome c release, and then causes the cells to
undergo apoptosis [17]. The antiapoptotic Bcl-2 family
proteins, Bcl-2 or Bcl-xL, prevent the Bax conformational
change by heterodimerizing with Bax, whereas various
BH3-only proteins induce Bax conformational change in
response to apoptotic stimuli [18-20].
The purpose of this study was to identify whether PUMA
up-regulation and Bax translocation contributed to E2F-1-
induced apoptosis in melanoma cells. Our data demon-
strated that E2F-1 leads to up-regulation of PUMA at the
transcription level in SK-MEL-2 cells. Sequence analysis
showed that there were six putative E2F-1 binding sites
within the PUMA promoter. Dual luciferase assay demon-
strated that E2F-1 could activate PUMA promoter activity
9.3-fold. The HCT116 PUMA knockout cell line was resist-
ant to E2F-1-mediated apoptosis in comparison with
HCT116 cells containing the wild-type PUMA gene. Over-
expression of a truncated E2F-1 protein that lacks the
transactivation domain failed to up-regulate PUMA pro-
moter, suggesting that PUMA may be an E2F-1 transcrip-
tional target. Overexpression of E2F-1-induced apoptosis
was also accompanied by Bax translocation from cytosol
to mitochondria. Taken together, these results suggest that
PUMA up-regulation and Bax translocation play an
important role in E2F-1-induced melanoma cell apopto-
sis.
Methods
Cell lines and culture conditions
Human melanoma cell line SK-MEL-2 (with mutant p53)
was purchased from ATCC and cultured in alpha-MEM
medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and penicillin/streptomycin (100
units/mL). The human colon cancer cell line HCT116
PUMA-/- and control cell line HCT116 PUMA+/+ were
generously provided by Dr. Bert Vogelstein [21] and were
maintained in McCoy's 5A medium supplemented with
10% FBS and penicillin/streptomycin (100 units/mL). All
cell culture reagents were obtained from Gibco/BRL
(Bethesda, MD). Cells were cultured in a 5% CO2 incuba-
tor at 37°C, and the medium was changed every 3 days.
Adenoviral vectors and infection conditions
Four replication-defective recombinant adenoviral vectors
were used. The Ad5CMV-E2F-1 (Ad-E2F-1) vector has
been deleted in the E1 subunit and contains the transgene
E2F-1 under the control of the cytomegalovirus (CMV)
promoter [3]. The Ad5CMV-LacZ (Ad-LacZ) was used as a
control vector that expresses nuclear-localized β-galactos-
idase under control of the CMV promoter [3]. The Ad/T-
E2FD vector expresses truncated E2F-1 protein, which
retains E2F-1 DNA-binding, but lacks its transactivation
domain. Expression of truncated E2F-1 from Ad/T-E2FD
was controlled by a tetracycline inducible promoter. The
Adeno-X Tet-off virus (AdTet-off) was obtained from
Clontech (Mountain View, CA) and was used at multiplic-
ity of infection (MOI) 5 as a helper virus to activate the tet-
racycline inducible promoter of Ad/T-E2FD. Where
indicated, doxycycline (Sigma, St. Louis, MO) was added
to a final concentration of 1 μg/mL. All vectors were prop-
agated in the 293 cell line, and titers were determined
using standard plaque assays [22].
The infection procedure used has been described in detail
previously [3]. Cells were plated into 6-well plates at 2 ×
105 cells/well or 24-well plates at 4 × 104 cells/well for SK-
MEL-2 cells and 1 × 105 cells/well in 24-well plate for
HCT116 cells. The following day, the media were
removed, and the adenoviral vectors were added in 200
μL of medium without FBS for 6-well plates or 100 μL of
medium for 24-well plates at indicated multiplicities of
infection (MOIs). Mock infection was performed by treat-BMC Cancer 2007, 7:24 http://www.biomedcentral.com/1471-2407/7/24
Page 3 of 12
(page number not for citation purposes)
ment of cells with vehicle (media) only. After 2 hours of
incubation at 37°C, fresh alpha-MEM with 5% FBS (for
SK-MEL-2 cells) or McCoy's 5A with 5% FBS (for HCT116
cells) was added to bring the final volume up to 2 mL for
6-well plates and 1 mL for 24-well plates. Cells were then
cultured at 37°C and harvested at selected time points for
analysis.
Luciferase-promoter assay
Cells were plated in a 12-well plate at 1 × 105 cells/well for
SK-MEL-2 cells or at 2.2 × 105 cells/well for HCT116
PUMA+/+ cells and cultured in medium containing 10%
FBS. Within 24 hours, cells were co-transfected with a
PUMA promoter construct and a phRL-CMV plasmid
(containing the cDNA encoding Renilla luciferase) by
using Lipofectamine 2000 transfection reagent (Invitro-
gen, Carlsbad, CA). Cells were infected with Ad-LacZ or
Ad-E2F-1 6 hours later. After 16 hours of infection, lysates
were collected and assayed for luciferase activity by using
the Dual Luciferase Reporter Assay System (Progema,
Madison, WI). Luciferase activity from untreated control
cells was used for the background signal. All of the luci-
ferase values were normalized to the Renilla luciferase rea-
dout values and expressed as x-fold induction relative to
that of Ad-LacZ infected cells.
The PUMA promoter (pBV-Luc) reporter construct has
been previously described [13] and was a kind gift from
Dr. Bert Vogelstein (The Howard Hughes Medical Insti-
tute, Baltimore, MD). The phRL-CMV plasmid was a kind
gift from Dr. Sham S. Kakar (University of Louisville, Lou-
isville, KY).
Real-time PCR analysis and Western blot analysis
Real-time PCR was performed using the SYBR Green PCR
Master Mix kit, according to the protocol of the manufac-
turer [ABI, Foster City, CA] Briefly, melanoma cells or
colon cancer cells were infected with Ad-E2F-1 or Ad-LacZ
at MOI 100. At indicated time points after infection, total
RNA was isolated using RNeasy mini kit, along with
RNase Free DNase set to remove any traces of DNA con-
tamination (QIAGEN, Valencia, CA). cDNA was prepared
from 500 ng of total RNA with TaqMan Reverse Transcrip-
tion Reagents (ABI/Roche, Branchburg, NJ). Real-time
PCR was performed using 12.5 ng of cDNA as a template
for each gene. Reactions were carried out in a 96-well
Optical Reaction plate (ABI) using the ABI Prism 7000
sequence detection system. Primers for the PUMA gene
have been described previously [23]. Data were analyzed
using the comparative CT method [24] and were presented
as mean ± standard deviation (SD) from two independent
experiments. Western blot analysis was performed as
described previously [4]. Human PUMA, E2F-1, and anti-
actin were detected using the antibodies ab9643-100 (1:
500, Abcam Ltd, Cambridge, UK), sc-251 (1:1000, Santa
Cruz, California, CA), and A-2066 (1: 5000, Sigma-
Aldrich, St. Louis, MO). Protein bands on film from West-
ern blots were scanned, and the optical density of the
bands was quantified using the NIH image 1.61 software.
Cytotoxicity and cell viability assay
Cytotoxicity of Ad-E2F-1 infection in HCT116 PUMA+/+
and HCT116 PUMA-/- cells was assessed by MTT assay.
Briefly, early passage PUMA-/- and PUMA+/+ cells were
cultured in a 24-well plate at 1 × 105 cells/well in 1 mL
medium. The next day, cells were infected at the indicated
MOI of Ad-E2F-1 or Ad-LacZ. Three days later, 10% of the
original volume (100 μL) of MTT (5 mg/mL MTT in PBS,
Sigma, St. Louis, MO) was added to each well and incu-
bated at 37°C for 4 hours. After incubation, 500 μL of
lysis buffer (10%SDS in 0.01N HCl) was added, and sam-
ples were incubated at 37°C overnight for complete cell
lysis. On the following day, cytotoxicity was assessed by
measuring the conversion of the tetrazolium salt, MTT, to
formazan through measurement of absorbance at 570
nm. The results are expressed as the percentage of absorb-
ance of the control (untreated) cells from triplicate sam-
ples.
For cell viability assay, cells were plated at 7 × 105 cells/
dish in 60 mm dishes and treated as above. Cell viability
was determined at indicated time points using the trypan
blue exclusion method. Cells were stained with trypan
blue (final concentration, 0.2%) for 5 minutes and
counted using a hemacytometer.
Immunocytochemistry
SK-MEL-2 cells, HCT116 PUMA+/+, and HCT116 PUMA-
/- cells were seeded on cover slips in 12-well plates and
cultured in a 5% CO2 incubator at 37°C. The following
day, cells were infected with Ad-E2F-1 or Ad-LacZ at MOI
100. Mock infection was performed by treatment of cells
with vehicle (media) only. After infection 24 hours, the
media was changed to fresh culture medium and cells
were incubated with MitoTracker Red 580 (Invitrogen
Corporation, Carlsbad, CA) with the final concentration
of 300 nM in 37°C for 40 minutes. The cover slips were
rinsed with warm medium twice and fixed with 3.7% for-
maldehyde in 37°C for 15 minutes. The cells were then
permeabilized with ice cold acetone for 5 minutes. Block-
ing was performed in PBS supplemented with 5% goat
serum. Primary antibody Bax (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) was applied at 1:100 at room tem-
perature for 45 minutes. Then, the cells were washed three
times for 30 minutes and incubated with the secondary
antibody (goat anti-mouse Alex 488 at 1:500) (Invitrogen
Corporation, Carlsbad, CA) at room temperature for 40
minutes. Cells were counterstained with 4',6-diamidino-
2-phenylindole (DAPI) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) at 200 nM for 2 minutes in room temper-BMC Cancer 2007, 7:24 http://www.biomedcentral.com/1471-2407/7/24
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ature. Finally, cells were washed extensively and mounted
with Mowiol (Calbiochem, La Jolla, CA). The scans were
done in a sequential mode to avoid channel crosstalk. Pic-
tures were taken on an Olympus Fluoview 500 confocal
microscope.
Determination of caspase-9 activity
The caspase-9 colorimetric assay kit (from R&D Systems,
Minneapolis, MN) was used for caspase-9 activity assay.
Briefly, cells were seeded in a 100-mm dish at 1 × 106
cells/dish for melanoma cells or 2 × 106 cells/dish for
HCT116 cells. The next day, cells were infected at the indi-
cated MOI of Ad-E2F-1 or Ad-LacZ. The 2 × 106 cells were
harvested and pelleted at indicated times. Cells were
resuspended in 50 μL of chilled lysis buffer, incubated on
ice for 10 minutes, and centrifuged for 1 minute in a
microcentrifuge (10,000 g). Supernatants (cytosolic
extract) were transferred to a fresh tube and put on ice to
assay protein concentration. Protein concentration was
adjusted with the cell lysis buffer. Then, 50 μL of the cell
lysate was added to 50 μL of 2× reaction buffer and 5 μL
of caspase-9 substrate (LEHD-pNA) and incubated at
37°C for 1 hour to test for protease activity by the addi-
tion of a caspase-specific peptide that is conjugated to the
color reporter molecule p-nitroanaline (pNA). The cleav-
age of the peptide by the caspase releases the chromo-
phore pNA, which can be quantitated at 405 nm. The level
of caspase activity in the cell lysate is directly proportional
to the color reaction. No cell lysates and no substrates
were used as blanks. The results were expressed as the fold
increase in Ad-E2F-1-treated cells over that of Ad-LacZ-
treated cells.
Results
E2F-1 leads to increased PUMA expression in SK-MEL-2 
cells
Our previous studies have shown that adenovirus-medi-
ated overexpression of E2F-1 can efficiently induce apop-
tosis in a wide spectrum of cancer cell lines. Due to the
importance of the Bcl-2 family members in the control of
cellular fate (survival versus apoptosis), we focused our
present study on determining whether PUMA, one of the
BH3 only family members, was involved in E2F-1-
induced cell apoptosis. We chose SK-MEL-2 melanoma
cell line because all of the other melanoma cell lines typi-
cally express p53, whereas only this cell line has mutant
p53, and there is no p73 expression after Ad-E2F-1 infec-
tion (unpublished data). We examined the effect of E2F-1
expression on PUMA mRNA expression over time. Quan-
titative real-time PCR analysis showed that a 2.6-, 5-, and
10-fold increase of PUMA mRNA levels was observed in
SK-MEL-2 cells after E2F-1 infection at 8 hours, 12 hours,
and 16 hours, respectively, compared to the Ad-LacZ con-
trol (Fig. 1A).
To validate the PUMA mRNA up-regulation findings after
E2F-1 treatment, we performed Western blotting to ana-
lyze the PUMA gene expression at the protein level. As
shown in Fig. 1B, the PUMA protein level increased at 8
hours and was still pronounced at 16 hours and 18 hours
post-infection with Ad-E2F-1. The alterations of the
PUMA protein level corresponded with changes in the
mRNA level. These data suggest that induction of PUMA
may be an important event in E2F-1-induced cell apopto-
sis.
Identification of a putative E2F-1 binding site in the human 
PUMA promoter
The fact that overexpression of E2F-1 induces expression
of PUMA suggests that the PUMA gene may be one of the
potential targets of E2F-1. The presence of E2F-1 respon-
sive elements in the PUMA promoter would be a strong
indication that E2F-1 regulates PUMA at the transcription
level. Thus, we performed sequence analysis to determine
whether any putative E2F-1 binding sites existed in the
PUMA gene promoter. A previous study showed that E2F-
1 interacts with all of the G-residues in the sequence
GGCGGGAAA, while the A-residues are not required for
DNA binding [25]. Six potential E2F-1 binding sites
(GGCGGG) were found at -63/-68, -73/-78, -79/-84, -
100/-105, -124/-129, and -132/-137 basic regions of the
PUMA promoter (the position is relative to the ATG initi-
ation codon). This further suggests that PUMA might be a
transcriptional target of E2F-1.
Ad-E2F-1 infection up-regulates the activity of the PUMA 
promoter
Although the above data suggests that E2F-1 transcription-
ally up-regulates the PUMA gene, the additional test is to
determine whether E2F-1 overexpression can transactivate
a chimeric construct in the PUMA promoter linked to a
reporter gene. For these experiments, we co-transfected
SK-MEL-2 cells with a PUMA promoter reporter plasmid
(PUMA promoter linked to a luciferase reporter gene, and
the PUMA promoter fragment was -428/+67 region of the
human PUMA promoter) and a phRL-CMV plasmid (con-
taining the cDNA encoding Renilla luciferase, used as an
internal control for transfection efficiency). After 6 hours
of transfection, the cells were infected with Ad-LacZ (as
control) and Ad-E2F-1. Luciferase activity was examined
after 16 hours of infection. Ad-E2F-1 infection increased
PUMA promoter activity by 9.3 fold in SK-MEL-2 cells
compared with the control cells infected with Ad-LacZ
(Fig. 2A). This result suggests that Ad-E2F-1 infection can
activate the PUMA promoter in SK-MEL-2 cells. This also
provides additional evidence that PUMA might be a tran-
scriptional target of E2F-1.BMC Cancer 2007, 7:24 http://www.biomedcentral.com/1471-2407/7/24
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E2F-1 leads to increased PUMA expression is dependent 
on its transactivation domain in SK-MEL-2 cells
To confirm that the transactivation function of E2F-1 is
required for the up-regulation of PUMA in SK-MEL-2 cells,
we performed PUMA promoter luciferase assay after infec-
tion with Ad/T-E2FD (an adenovirus vector expressing
truncated E2F-1 protein without its transactivation
domain) at MOI 100. Ad/T-E2FD infection did not
increase PUMA promoter activity in SK-MEL-2 cells com-
pared with the control cells infected with Ad-LacZ (Fig.
2B). These data indicate that the transactivation domain
of E2F-1 is required for the increase of PUMA in SK-MEL-
2 cells.
Loss of PUMA protects the HCT116 cells against E2F-1-
induced cell death
To further evaluate the importance of the PUMA gene in
Ad-E2F-1-induced apoptosis, we took advantage of a
PUMA knockout cell line. We reasoned that if PUMA is
truly a mediator in E2F-1-induced apoptosis, there should
be significant resistance to E2F-1-induced cell death in
PUMA knockout cells. The HCT116 PUMA knockout cell
line (PUMA-/-) and the HCT116 control cell line
(PUMA+/+) were infected with Ad-E2F-1 at the indicated
MOI and indicated times and were then subjected to anal-
ysis of cell viability and a cytotoxicity assay. As shown in
Fig. 3A, HCT116 PUMA-/- cells were more resistant to
A. Up-regulation of PUMA at the transcription level after Ad-E2F-1 expression in SK-MEL-2 cells Figure 1
A. Up-regulation of PUMA at the transcription level after Ad-E2F-1 expression in SK-MEL-2 cells. SK-MEL-2 cells 
were infected with Ad-E2F-1 at MOI 100. Ad-LacZ was used as control. Cells were harvested after infection at 8 hours, 12 
hours, and 16 hours. Real-time PCR was performed as described in Materials and Methods. β-actin was used as an internal con-
trol. The bar graphs are expressed as fold increase relative to Ad-LacZ-infected cells adjusted for β-actin. Each of the experi-
ments is a representation of two independent experiments performed in duplicate. After adjustment for β-actin mRNA 
expression, real-time PCR results showed a 2.6-, 5-, and 10-fold induction at the PUMA mRNA level after 8 hours, 12 hours 
and 16 hours of Ad-E2F-1 infection, respectively. B. Up-regulation of PUMA at the protein level after Ad-E2F-1 
expression in SK-MEL-2 cells. Western blot analysis of PUMA at indicated time points after Ad-LacZ or Ad-E2F-1 infec-
tion. Anti-actin was used to show the equal loading and transfer in each lane. E2F-1 expression was also shown at the indicated 
time points to correlate with PUMA expression. PUMA/actin showed the ratio of the scanned optical density of each protein 
band. In SK-MEL-2 cells, PUMA protein level increased at 8 hours post-infection with Ad-E2F-1 and was still pronounced at 16 
hours and 18 hours post-infection with Ad-E2F-1.
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E2F-1-induced cell death, while HCT116 PUMA+/+ cells
were more sensitive to E2F-1-induced cell death, espe-
cially at a higher MOI (MOI 50). After 4 days of Ad-E2F-1
infection, analysis of HCT116 PUMA-/- cells revealed
15% more viable cells than PUMA+/+ cells (Fig. 3B). MTT
assay also showed that loss of the PUMA gene enhanced
survival of HCT116 cells infected with Ad-E2F-1 com-
pared with Ad-LacZ infection. After 4 days of Ad-E2F-1
infection at MOI 50, analysis of HCT116 PUMA-/- cells
revealed 18% more viable cells than PUMA+/+ cells by
MTT test (data not shown). To exclude the possibility that
the difference in cell viability is due to different transduc-
tion efficiency of adenoviral vectors, we performed a β-
galactosidase assay [3]. HCT116 PUMA+/+ and HCT116
PUMA-/- cell lines were infected with Ad-LacZ at MOI of
100. Transduction efficiency was determined by measur-
ing the blue cells after cytochemical staining with X-gal 24
hours after infection. Equivalent transduction efficiency
(approximately 70%) was observed in both cell lines
(data not shown). These data suggest that loss of PUMA
protects cells against E2F-1-mediated cell death, and up-
regulation of PUMA plays an important role in E2F-1-
induced cell death.
Overexpression of E2F-1 increases the endogenous PUMA 
expression in HCT116 cells
To confirm the involvement of the PUMA gene in E2F-1-
induced apoptosis in the HCT116 PUMA+/+ cell line, we
A. E2F-1 expression up-regulates the activity of the PUMA promoter in SK-MEL-2 cells Figure 2
A. E2F-1 expression up-regulates the activity of the PUMA promoter in SK-MEL-2 cells. SK-MEL-2 cells were co-
transfected with a total of 0.88 μg of DNA, including 0.8 μg of PUMA promoter reporter plasmid and 0.08 μg phRL-CMV plas-
mid (as an internal control) in a 12-well plate by using Lipofectamine 2000 transfection reagent. After 6 hours of transfection, 
the cells were infected with Ad-LacZ (as control) and Ad-E2F-1. Luciferase activity was examined 16 hours later as described in 
the manufacturer's protocol using the Dual Luciferase Reporter Assay System (Promega). The bar graphs depict the fold of 
activation in the luciferase assay after normalization for Renilla luciferase readout values. Each of the experiments is a represen-
tation of at least three independent experiments performed in duplicate. B. Transactivation domain of E2F-1 was 
required for the up-regulation of the PUMA promoter in SK-MEL-2 cells. SK-MEL-2 cells were co-transfected as in 
Fig. 2A. After 6 hours of transfection, the cells were infected with Ad/T-E2FD (expressing truncated E2F-1) at MOI 100 plus 
AdTet-off at MOI 5 (using as a helper virus), Ad/T-E2FD at MOI 100 plus AdTet-off at MOI 5, and doxycycline 1 μg/ml or Ad-
LacZ at MOI 100. Luciferase activity was examined 16 hours later as in Fig. 2A. The bar graphs depict the fold of activation in 
the luciferase assay after normalization for Renilla luciferase readout values. Each of the experiments is a representation of at 
least three independent experiments performed in duplicate.
0
2
4
6
8
10
12
Ad-LacZ Ad-E2F-1
f
o
l
d
 
a
c
t
i
v
a
t
i
o
n
0
0.25
0.5
0.75
1
1.25
Ad-LacZ Ad/T-
E2FD+Ad-tet-
off+Dox
Ad/T-
E2FD+Ad-tet-
off
f
o
l
d
 
a
c
t
i
v
a
t
i
o
n
AB
E2F-1
actin
T-E2F D
actinBMC Cancer 2007, 7:24 http://www.biomedcentral.com/1471-2407/7/24
Page 7 of 12
(page number not for citation purposes)
again performed promoter assay, real-time PCR, and
Western blot analysis in this cell line after treatment with
Ad-E2F-1. As expected, the PUMA promoter was activated
2.2-fold after Ad-E2F-1 infection in HCT116 PUMA+/+
cells (Fig. 4A). Similarly, real-time PCR showed a 2-fold
increase in PUMA expression in HCT116 PUMA+/+ cells
at 6 hours after Ad-E2F-1 infection compared to cells
infected with the Ad-LacZ control (data not shown). West-
ern blotting results still showed that the PUMA protein
level was increased at 12 hours and 16 hours of infection
with Ad-E2F-1. The increased PUMA protein expression
corresponded with the up-regulation of PUMA mRNA
after Ad-E2F-1 infection in this cell line (Fig. 4B).
Overexpression of E2F-1 is associated with Bax activation 
and translocation to mitochondria
Recent evidence implicates Bax to be an important medi-
ator of PUMA-activated apoptotic signals. To examine the
possibility of PUMA eliciting Bax mitochondrial translo-
cation when PUMA is transcriptionally up-regulated by
E2F-1, we performed immunocytochemistry to study the
cellular distribution of Bax with confocal microscope.
Confocal microscopy revealed that Bax was diffusely dis-
tributed throughout the cytosol after 24 hours of Ad-LacZ
infection or mock infection in SK-MEL-2 cells (Fig. 5a).
After 12 hours of Ad-E2F-1 infection, Bax has the similar
cytosol distribution pattern as that in mock or Ad-LacZ-
infected cells (data not shown). However, after 24 hours
of Ad-E2F-1 infection, Bax clustered and co-localized with
mitochondria (Fig. 5b). An overlay of the three stains is
given in yellow, which shows co-localization of Bax in
mitochondria. Similarly, in HCT116 PUMA+/+ cells, we
also observed that Bax was diffusely distributed through-
out the cytosol after 24 hours of Ad-LacZ or mock infec-
tion (Fig. 5c). Bax clustered and co-localized with the
mitochondria after 24 hours of Ad-E2F-1 infection (Fig.
5d). Thus, our results suggest that PUMA up-regulation
and subsequently Bax translocation appear to contribute
to E2F-1-induced apoptotic pathway.
Activation of caspase-9 accompanied with E2F-1-induced 
PUMA overexpression and apoptosis
Since PUMA up-regulation and Bax translocation have
been shown to release cytochrome C from the mitochon-
dria and activate caspase-9 through mitochondrial path-
way [12,18], we performed caspase-9 activity assay to
evaluate downstream effects of PUMA and Bax in E2F-1-
induced apoptosis. SK-MEL-2, HCT116 PUMA+/+, and
HCT116 PUMA-/- cells were infected with Ad-E2F-1 and
lysed at indicated time points to collect intracellular con-
Resistance in response to E2F-1 expression in the HCT116 PUMA-/- cell line compared to the HCT116 PUMA+/+ cell line by  cell viability assay Figure 3
Resistance in response to E2F-1 expression in the HCT116 PUMA-/- cell line compared to the HCT116 
PUMA+/+ cell line by cell viability assay. Both floating and adherent cells were harvested, counted, and scored at indi-
cated time points. Viability was assessed using the trypan blue exclusion method. Results are expressed as the percent viable 
cells at each point and values represent the means ± SD (bars) of three independent experiments. A. HCT116 PUMA-/- and 
HCT116 PUMA+/+ cell lines were treated by infection with Ad-LacZ or Ad-E2F-1 at indicated MOI. The viability was assessed 
at day 4 after virus infection. B. Time course of cell viability of HCT116 PUMA-/- and HCT116 PUMA+/+ cells in response to 
Ad-LacZ or Ad-E2F-1 infection at MOI of 50.BMC Cancer 2007, 7:24 http://www.biomedcentral.com/1471-2407/7/24
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tents. As shown in Figure 6, caspase-9 activity was induced
after Ad-E2F-1 treatment in SK-MEL-2 and HCT116
PUMA+/+ cell lines, but not in control HCT116 PUMA+/
+ cells infected with Ad-LacZ. In the SK-MEL-2 cell line,
caspase-9 activity was induced 3.7-fold after 48 hours of
Ad-E2F-1 infection. In the HCT116 PUMA+/+ cell line,
caspase-9 activity was induced 3.0 fold after 48 hours of
Ad-E2F-1 infection. In HCT116 PUMA-/- cells, caspase-9
activity was also increased after Ad-E2F-1 infection, but to
a lesser degree (1.5 fold after 48 hours of Ad-E2F-1 infec-
tion). These data suggest that PUMA likely plays a role in
mediating Ad-E2F-1-induced apoptosis through the cyto-
chrome C/Apaf-1-dependent pathway.
Discussion
To date, three pathways of E2F-1-induced apoptosis have
been demonstrated: (1)  A p53-dependent pathway
through the stabilization of p53 by E2F-1; (2) p53-inde-
pendent pathways through direct up-regulation of apop-
totic related genes by E2F-1, such as p73 and PKR [26,27];
and  (3)  blocking of anti-apoptotic pathways through
down-regulation or inhibition of anti-apoptotic mole-
cules such as Bcl-2 and Mcl-1 [8]. Recently, a rapidly grow-
ing number of pro-apoptotic genes have been shown to be
regulated by E2F-1 expression. Hershko et al [28] have
demonstrated that E2F-1 up-regulates the expression of
the pro-apoptotic BH3-only proteins, PUMA, Noxa, Bim,
and Hrk/DP5, through a direct transcriptional mecha-
nism in NIH3T3 cells. Another study, which screened a
siRNA-expression library, identified one of the novel
pathways involved in thapsigargin-induced apoptosis in
HCT116 cells, in which endogenous E2F-1 might regulate
TG-induced cell apoptosis via regulation of the expression
of PUMA [29]. Loss of the PUMA gene in cancer cells has
A. E2F-1 expression up-regulates the activity of the PUMA promoter in HCT116 PUMA+/+ cells Figure 4
A. E2F-1 expression up-regulates the activity of the PUMA promoter in HCT116 PUMA+/+ cells. HCT116 
PUMA+/+ cells were co-transfected with a total of 0.82 μg of DNA, including 0.8 μg of PUMA promoter reporter plasmid and 
0.02 μg phRL-CMV plasmid (as an internal control) in a 12-well plate by using Lipofectamine 2000 transfection reagent, and 
then processed as in Fig. 2A. 4B Up-regulation of PUMA at the protein level after Ad-E2F-1 expression in HCT116 
PUMA+/+ cells. Western blot analysis of PUMA was performed in HCT116 PUMA+/+ cells at indicated time points as in Fig. 
1B. PUMA/actin showed the ratio of the scanned optical density of each protein band. PUMA protein level was increased at 12 
hours and 16 hours of infection with Ad-E2F-1.
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been shown to cause cells to be resistant to a variety of
apoptotic stimuli such as DNA damage, microtubule-
damaging agents [30], and ER stressor thapsigargin-
induced apoptosis [31]. However, whether PUMA con-
tributes to E2F-1-induced cancer cell apoptosis has not
been fully elucidated. Our studies indicate that E2F-1
overexpression results in up-regulation of the pro-apop-
totic PUMA gene at the transcription and protein levels.
Sequence analysis shows that the human PUMA promoter
contains six E2F-1 binding sites. Promoter assay demon-
strates that E2F-1 can activate the PUMA promoter 9.3
fold in SK-MEL-2 cells. Our data also suggest that HCT116
PUMA knockout cells (PUMA-/-) are more resistant in
response to E2F-1-induced apoptosis than wild-type
PUMA cells (PUMA+/+). Activation of the PUMA pro-
moter upon E2F-1 expression was observed by using Luci-
ferase reporter assay in the HCT116 wild-type PUMA cell
line (PUMA+/+). Furthermore, when we performed real-
time PCR and Western blot analysis, the PUMA gene was
up-regulated at both the transcriptional level and the pro-
tein level in this cell line. Collectively, all these data sup-
port the conclusion that PUMA is an important mediator
of E2F-1-induced cancer cell apoptosis.
The E2F-1 protein contains a related DNA binding
domain, dimerization domain, and a transactivation
domain. Previous studies showed that the transactivation
domain of E2F-1 is not required for E2F-1-induced apop-
Bax mitochondrial translocation after Ad-E2F-1 expression in SK-MEL-2 cells and HCT116 PUMA+/+ cells Figure 5
Bax mitochondrial translocation after Ad-E2F-1 expression in SK-MEL-2 cells and HCT116 PUMA+/+ cells. SK-
MEL-2 cells (a,b) and HCT116PUMA+/+ cells (c,d) were infected with Ad-LacZ and Ad-E2F-1. After 24 hours of infection, 
cells were stained with Mitotracker Red 580 and Bax (green), then counterstained with DAPI (blue) as described in the Meth-
ods. After 24 hours of Ad-E2F-1 infection in SK-MEL-2 cells (b) and HCT116PUMA+/+ cells (d), Bax clustered and translo-
cated to mitochondria (an overlay of the three stains is given in yellow, which shows co-localization of Bax in mitochondria).
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tosis. In order to investigate the different apoptotic mech-
anisms of the full-length E2F-1 and E2F-1 without the
transactivation domain, we constructed a new adenovirus
vector, Ad/T-E2FD, which retains E2F-1 DNA-binding
domain, but lacks its transactivation domain. Overexpres-
sion of a truncated E2F-1 protein lacking its transactiva-
tion domain failed to stimulate transcription from the
PUMA promoter, suggesting that the transactivation
domain is required for PUMA up-regulation in E2F-1-
induced melanoma cell apoptosis.
PUMA was first identified as a novel gene by screening for
p53-inducible target genes [12,13]. Studies with knockout
mice or human cancer cells demonstrate that PUMA is
essential for p53-dependent apoptosis induced by DNA
damage [21,32,33]. Recently, Chipuk et al [34] report that
PUMA provides a critical link that couples p53 transcrip-
tion-dependent and transcription-independent functions.
Genetic studies demonstrate the importance of PUMA for
p53-mediated cell death and reinforce the control of
PUMA to modulate the p53 response [35,36]. However,
other studies showed that the activity of the PUMA pro-
moter could be up-regulated by E2F-1 in a p53-independ-
ent manner [28]. Involvement of p53 in the E2F-1-
induced increase of PUMA was also excluded by the find-
ing that ectopic expression of E2F-1 in mouse primary
fibroblasts derived from p53-null mice resulted in ele-
vated PUMA levels [28]. Another study showed that
PUMA mRNA was induced by p53-independent apoptotic
stimuli [37]. In this study, we showed that PUMA pro-
moter is activated by E2F-1 in SK-MEL-2 cells which
express mutant p53. These data suggest that up-regulation
of PUMA by E2F-1 overexpression in melanoma cells may
not require functional p53.
Apoptosis can be initiated by a wide array of stimuli,
including multiple signaling pathways that, for the most
part, converge at the mitochondria. Several Bcl-2 family
members, including PUMA and Bax, contribute to and
regulate the apoptosis. The death effector, Bax, plays an
essential role in the mitochondrial pathway of apoptosis.
In the absence of death signals, Bax exists in the cytosol in
an inactive form, but it becomes activated by a conforma-
tional change and is translocated to mitochondria during
apoptosis. It has been reported that proapoptotic BH3-
only protein, PUMA, promotes Bax mitochondrial trans-
location [38]. Here, our data showed that PUMA up-regu-
lation after E2F-1 overexpression was subsequently
accompanied by Bax mitochondrial translocation. Both
PUMA and Bax function by releasing cytochrome C from
mitochondria. The most important consequence of cyto-
chrome C discharge is the activation of procaspase-9. This
is facilitated by Apaf-1 and cytochrome C in the presence
of dATP or ATP. Activated caspase-9 then triggers the
processing and activation of the downstream caspase-3
and capase-7 that culminate in apoptotic cell death [39].
Here, we show that overexpression of E2F-1 causes induc-
tion of PUMA, mitochondrial translocation of Bax, which
Activation of caspase-9 was accompanied by PUMA-mediated E2F-1-induced apoptosis Figure 6
Activation of caspase-9 was accompanied by PUMA-mediated E2F-1-induced apoptosis. 2 × 106 of SK-MEL-2 (A), 
HCT116 PUMA+/+ cells (B), and HCT116PUMA-/- cells (C) were infected with Ad-E2F-1 or Ad-LacZ and lysed at indicated 
time points to collect their intracellular contents. The cell lysates were assayed for caspase-9 activity by measuring the diges-
tion of p-nitroanaline (pNA) as a substrate. The OD405 values were measured, and the percentage values were compared with 
Ad-LacZ infected cells as indicated. Caspase-9 activity was induced 3.6 fold, 3.0 fold, and 1.5 fold after 48 hours of Ad-E2F-1 
infection in SK-MEL-2 cells, HCT116 PUMA+/+ cells, and HCT116PUMA-/- cells, respectively.
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consequently leads to activation of caspase-9 and eventual
apoptosis.
In this study, we noticed that HCT116 PUMA+/+ cells
were more sensitive to E2F-1-induced cell death than
HCT116 PUMA-/- cells. While loss of PUMA protected the
HCT116 cells against E2F-1-induced cell death, the
HCT116 PUMA-/- cells eventually underwent cell death
after Ad-E2F-1 infection. Furthermore, in HCT116 PUMA-
/- cells, caspase-9 activity was also increased after Ad-E2F-
1 infection, albeit at a much lower level than SK-MEL-2
and HCT116 PUMA+/+ cells. Obviously, we cannot
exclude other apoptotic pathways other than PUMA
involved in Ad-E2F-1-induced cell apoptosis, such as p14/
p19ARF, PKR, and other anti-apoptotic molecules such as
Bcl-2 and Mcl-1. The results we observed in SK-MEL-2
melanoma cells may not be generalizable to all cancer cell
types.
Conclusion
In conclusion, our results suggest that induction of the
pro-apoptotic molecule PUMA and subsequent Bax acti-
vation contributes to E2F-1-induced apoptosis in
melanoma cells. Identification of specific genes in cancer
cell apoptotic pathways may lead to the development of
new cancer therapeutic strategies. The signaling pathways
provided here further enhance our understanding of the
mechanisms of E2F-1-induced cancer cell apoptosis,
which has the potential for future clinical applications in
cancer therapy.
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